meta_pixel
Tapesearch Logo
WSJ Tech News Briefing

DeekSeek Resists Bringing on Investors

WSJ Tech News Briefing

The Wall Street Journal

News, Tech News

4.61.6K Ratings

🗓️ 17 March 2025

⏱️ 11 minutes

🧾️ Download transcript

Summary

The Chinese AI company doesn’t want to bother with funding—at least not right now. WSJ reporter Rebecca Feng discusses why DeepSeek is so hesitant. Plus, how will federal funding cuts impact drug development? WSJ enterprise technology bureau chief Steven Rosenbush explains the impact on the bioscience industry. Shara Tibken hosts. Sign up for the WSJ's free Technology newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Transcript

Click on a timestamp to play from that location

0:00.0

Here's the truth about AI. AI is only as powerful as the platform it's built into. Service Now puts AI to work for people across your business, removing friction and frustration for your employees, supercharging productivity for your developers, providing intelligent tools for your service agents to make customers happier, all built into a single platform you can

0:22.0

use right now. That's why the world works with ServiceNow. Visit ServiceNow.com

0:27.9

slash UK slash AI for people. Welcome to Tech News briefing. It's Monday, March 17th. I'm Shara Tipkin for the Wall Street Journal.

0:40.7

Federal funding cuts are putting the bioscience industry at risk. What do these cutbacks mean for the future of drug development in the U.S.?

0:49.5

Then, DeepSeek shook up the world of artificial intelligence when it introduced its chatbide.

0:55.7

But that doesn't mean it's ready to take on investors.

0:58.9

Our reporter Rebecca Feng explains why the Chinese startup isn't in a hurry to get outside investment.

1:08.2

But first, the bioscience industry is facing federal funding cuts.

1:13.7

As part of the Trump administration's efforts to save money, it's freezing grants that universities

1:19.5

count on to fund their research.

1:22.3

Courts have blocked the cuts, but it's still causing uncertainty in the bioscience industry.

1:28.3

And that uncertainty could threaten drug development and the U.S.'s leadership in the fields.

1:33.8

Stephen Rosenbush, Bureau Chief of the Journal's Enterprise Technology Group, joins us now with more.

1:40.2

Stephen, how does funding usually work?

1:42.5

I spoke to researchers at the University of Washington in the biochemistry department,

1:48.8

which includes the Institute for Protein, design one of their chief investigators,

1:53.9

David Baker won a Nobel Prize for his work last year, designing proteins, not found in nature.

2:00.3

This group relies on the government for around

2:03.6

90% of its funding. Typically, these grants are paid to support research projects that can go on

2:11.1

for four or five years. Then they may conclude or they may renewed for another four or five years.

2:18.0

So these programs are functioning now, but there's a lot of uncertainty.

2:22.0

How are universities adapting?

...

Transcript will be available on the free plan in -11 days. Upgrade to see the full transcript now.

Disclaimer: The podcast and artwork embedded on this page are from The Wall Street Journal, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of The Wall Street Journal and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2025.